NASDAQ:CLVS
Delisted
Clovis Oncology Stock News
$0.151
+0 (+0%)
At Close: Apr 19, 2023
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.5
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
08:00am, Friday, 20'th Nov 2020
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
10:43am, Friday, 06'th Nov 2020
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript
07:40pm, Thursday, 05'th Nov 2020
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript
Clovis Oncology Announces Third Quarter 2020 Operating Results
08:05am, Thursday, 05'th Nov 2020
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clinical dev
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
08:02am, Thursday, 05'th Nov 2020
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Return On Capital Employed Overview: Clovis Oncology
02:36pm, Tuesday, 18'th Aug 2020
During Q2, Clovis Oncology's (NASDAQ: CLVS) reported sales totaled $39.89 million. Despite a 0.78% in earnings, the company posted a loss of $82.65 million. Clovis Oncology collected $42.56 million in
Clovis Rubraca Data, And Other News: The Good, Bad And Ugly Of Biopharma
11:52am, Tuesday, 18'th Aug 2020
Clovis reports positive data from TRITON clinical trial. Interpace Biosciences sinks on potential compliance roadblocks.
Why Clovis Oncology's Stock Is Trading Higher Today
07:13pm, Monday, 17'th Aug 2020
Clovis Oncology (NASDAQ:CVLS) shares are trading higher on Monday after the Journal Of Clinical Oncology published data from the Phase 2 TRITON2 study of Rubraca for the treatment of mCRPC in patients
JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
03:44pm, Friday, 07'th Aug 2020
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
11:10pm, Thursday, 06'th Aug 2020
Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology Announces Second Quarter 2020 Operating Results
08:05pm, Thursday, 06'th Aug 2020
Clovis Oncology Announces Second Quarter 2020 Operating Results
The Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market will grow by USD 810.23 mn during 2020-2024
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in ...
